Login
$BCAX
$9.70 -$0.32 (3.19%) Live

$BCAX 8-K SEC Filings

Filed On Filing
09 Nov 2026 8-K: Results of Operations and Financial Condition

Achieved substantial enrollment in FORTIFI-HN01 pivotal trial in 1L R/M HPV-negative HNSCC; topline results from interim analysis expected in mid-2027

25 Aug 2026 8-K: Entry into a Material Definitive Agreement

This SUB-SUBLEASE AGREEMENT (this “Sub-Sublease”) is made as of August 21, 2026 (the “Effective Date”), by and between WAYFAIR LLC, a Delaware limited liability company having an office at 4 Copley Place, Boston, Massachusetts 02116 (“Su...

11 Aug 2026 8-K: Results of Operations and Financial Condition

Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth

28 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

BOSTON, July 28, 2026 – Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced the appointments of Je...

10 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2026, Bicara Therapeutics Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in ...

21 May 2026 8-K: Other Events

Ficerafusp Alfa Plus Pembrolizumab Demonstrated Differentiated Three-Year Overall Survival and Deep Responses Driven by TGF-β Inhibition in 1L R/M HPV-Negative HNSCC

11 May 2026 8-K: Results of Operations and Financial Condition

Study to evaluate ficerafusp alfa in combination with pembrolizumab as a loading and every-three-week maintenance regimen in 1L R/M HPV-negative HNSCC expected to initiate in Q3 2026

30 Mar 2026 8-K: Results of Operations and Financial Condition

-- Selected 1500mg weekly of ficerafusp alfa as the optimal dose and initiated Phase 3 of the FORTIFI-HN01 pivotal trial; interim analysis expected mid-2027 --

26 Feb 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition

Bicara Therapeutics Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several Underwriters named in Schedule I hereto (the “Underwriters”) (i) 7,175,000 shares of its common stock, par value $0.0001 per shar...

19 Feb 2026 8-K: Other Events

Ficerafusp Alfa 2000mg Q2W Demonstrates Deep, Durable Responses in 1L R/M HPV-Negative HNSCC and Supports Development of Less Frequent Dosing Regimen

12 Jan 2026 8-K: Other Events

Selected 1500 mg of ficerafusp alfa as the optimal dose for the treatment of 1L HPV-negative R/M HNSCC in Phase 3 FORTIFI-HN01 pivotal study

08 Dec 2025 8-K: Regulation FD Disclosure; Other Events

ESMO Asia 2025 Clinical Update December 6, 2025 FICERA: enabling tumor penetration to drive deep and durable responses in HPV-neg HNSCC

10 Nov 2025 8-K: Results of Operations and Financial Condition

Granted FDA Breakthrough Therapy Designation for ficerafusp alfa in combination with pembrolizumab in 1L HPV-negative R/M HNSCC

12 Aug 2025 8-K: Results of Operations and Financial Condition

Updated data from Phase 1/1b trial presented at 2025 ASCO Annual Meeting demonstrated deep and durable responses in 1L HPV-negative R/M HNSCC

12 Jun 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 9, 2025, Bicara Therapeutics Inc. (the “Company”) held its 2025 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals at the Annual Meeting, each of which is described in more detail in ...

06 Jun 2025 8-K: Entry into a Material Definitive Agreement

On June 2, 2025, Bicara Therapeutics Inc. (the “Company”) entered into a Sublease Agreement (the "Sublease) with J.W. Childs Associates, L.P, (the “Sublandlord”), effective upon receipt of the consent of Columbia Reit – 116 Huntington, L...

13 May 2025 8-K: Results of Operations and Financial Condition

Updated data from ongoing Phase 1/1b trial in 1L R/M HNSCC to be presented at 2025 ASCO Annual Meeting

27 Mar 2025 8-K: Results of Operations and Financial Condition

Dosing commenced in FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC

13 Jan 2025 8-K: Regulation FD Disclosure

Exhibit 99.1 Fighting cancer with precision and power. Corporate Presentation | January 2025 © 2024 - 2025 Bicara Therapeutics

12 Nov 2024 8-K: Results of Operations and Financial Condition; Regulation FD Disclosure

On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support